

Press release

Contact:
Jeff Bork, President and CEO
Tel: +46 734 22 16 60

Biotage AB
Kungsgatan 76
SE-753 18 Uppsala
Tel+46 18 56 59 00
www.biotage.com

No sales increase in the third quarter due to delayed deliveries

Uppsala 5 October 2004

Deliveries of the new system for purification of drug compounds, SPX, that Biotage launched in the summer have been delayed three months. Therefore, estimated sales for the third quarter is between 83 and 85 MSEK.

The delay of the SPX systems depends on software development delays. The software is now finished and the systems are being delivered to customers. This means that the sales increase from the earlier announced large orders are estimated to appear in the fourth quarter.

Further information will be presented in the interim report for January to September 2004, which will be published October 21, 2004.

About Biotage

Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. Customers include the worlds top 30 pharmaceutical companies, 20 largest biotech companies and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, Japan and several European countries. Biotage has approx. 250 employees and had pro forma sales of 362 MSEK in 2003. Biotage is listed on the Stockholm stock exchange. Website: www.biotage.com

Certain statements in this press release are forward-looking. These may be identified by the use of forward looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotage's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.